Global /United States /Healthcare /Biotechnology /CADL

Candel Therapeutics, Inc.

CADL

• NASDAQ: CADL • Delayed

6.18USD -0.3%

As of 14 June 2026, Candel Therapeutics, Inc. has a market cap of $452.67M USD, ranking #15813 globally and #2708 in the United States. It ranks #1412 in the Healthcare sector, and #272 in the Biotechnology industry.

Global Rank

15813

Country Rank

2708

Sector Rank

1412

Industry Rank

272

Key Stats

Market Cap

$452.67MUSD

Enterprise Value

$385.63MUSD

EBITDA (TTM)

-$47.33MUSD

Net Income (TTM)

-$38.18MUSD

PB Ratio

6.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Paul-Peter Tak open_in_new

Employees

Founded

1999

IPO

27 Jul 2021

Website

candeltx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.3%	-16%	28%	7.7%	10%	9.4%	24%	379%	7%

News

CADL Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CADL Candel Therapeutics Inc ISIN: US1374041093 Shares Out.: Shares Outstanding: 73.27M¹ Shares Float: 57.904M² TV: TradingView: NASDAQ: CADL SA: Stock Analysis: NASDAQ: CADL YF: Yahoo Finance: CADL GF: Google Finance: NASDAQ: CADL NQ: NASDAQ: CADL BA: Barron's: CADL MS: Morningstar: XNAS: CADL	6.18 USD	TV: TradingView: NASDAQ: CADL SA: Stock Analysis: NASDAQ: CADL YF: Yahoo Finance: CADL GF: Google Finance: NASDAQ: CADL NQ: NASDAQ: CADL BA: Barron's: CADL MS: Morningstar: XNAS: CADL

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 40K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 35K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 6K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 6K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 5K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 4K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 10K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 10K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 9K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 9K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 6K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 6K%	-	Germany

chevron_leftBack